Skip to content

The effective components of feedback from Routine Outcome Monitoring (ROM) in youth mental health care.

The effective components of feedback from Routine Outcome Monitoring (ROM) in youth mental health care.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON29233
Enrollment
432
Registered
2013-11-04
Start date
2014-01-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

randomized controlled trial (RCT)/gerandomiseerd vergelijkend onderzoek, Routine Outcome Monitoring (ROM)/monitoren van zorg, feedback, children/kinderen, adolescents/adolescenten, parents/ouders, mental health care/geestelijke gezondheidszorg (GGZ), clinical support tools, treatment support measure (TSM), case consultation/intervisie, symptom severity/ernst van de klachten, quality of life/kwaliteit van leven, satisfaction/tevredenheid, number of sessions/aantal sessies, length of treatment/duu

Interventions

We will examine three different forms of feedback from ROM in youth mental health care through a three-arm parallel group randomized controlled trial. Randomization will be stratified by age of the ch

Sponsors

Radboud University Nijmegen Medical Centre, Pro Persona Jeugd Arnhem, Pro Persona Jeugd Ede, Pro Persona Jeugd Nijmegen, Pro Persona Jeugd Tiel. Sponsor: Radboud University Nijmegen Medical Centre Address: Geert Grooteplein-Zuid 10 Postalcode: 6525 GA City: Nijmegen Country: The Netherlands Telephone: +31 (0)24 361 11 11 Fax: +31 (0)24 354 05 76 E-mail: - Remarks : Postbus 9101, 6500 HB Nijmegen Sponsor: Pro Persona Jeugd Arnhem Address: De Braamberg - Wagnerlaan 2 Postalcode: 68
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The study takes place in all outpatient youth departments (in Arnhem, Ede, Nijmegen and Tiel) of a large mental health care institution in the eastern part of The Netherlands. All families with children and adolescents between 4 and 17 years that are referred to these youth departments receive information about the study. If the child is between 4 and 11 years old, then parents are approached to participate in the study. If the child or adolescent is between 12 and 17 years old, then the child or adolescent is approached to participate in the study. We will include children and adolescents with all kinds of mental health problems (e.g developmental disorders, anxiety disorders and mood disorders) and all kinds of treatment (e.g individual treatment and group treatment, cognitive-behavioral treatment and solution-focused treatment, frequent or irregular treatment) in the study. The children, adolescents and parents that agree to participate sign an informed consent form.

Exclusion criteria

Exclusion criteria: The only exclusion criterion is insufficient understanding of the Dutch language by the child, adolescent or parents.

Design outcomes

Primary

MeasureTime frame
Our primary outcome is symptom severity and will be measured with the Dutch version of the Strengths and Difficulties Questionnaire (SDQ).

Secondary

MeasureTime frame
1) Quality of life : measured with the KIDSCREEN-27 parent version and the KIDSCREEN-52 child-adolescent version. 2) Satisfaction with treatment: measured with the Jeugdthermometer child version and the Jeugdthermometer parent versions about the treatment of the child and about the parenting skills training. 3) Number of sessions: will be counted for each client. 4) Length of treatment: will be registered in days for each client. 5) Dropout: will be calculated as the percentage of clients that abandon treatment (registered as unilateral decision to end treatment) in each feedback group. We will also examine the role of being not on track (not responding to treatment).

Contacts

Public ContactA.M.S. Sonsbeek, van

Postaddress: Radboud University Nijmegen, PO Box 9104

m.van.sonsbeek@propersona.nl+31 (0)24 361 57 67

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)